LifeVantage announces new results from second human study on GLP-1 System

LifeVantage (LFVN) announced new results from its second human clinical study on the MindBody GLP-1 System, revealing even more compelling outcomes across a broader participant base. When researchers combined data from the most recent clinical trial completed in April 2025, with findings from the initial trial conducted in fall 2024, the average increase of GLP-1 improved to over 200% – a significant rise from the previously reported 140%. GLP-1 is a critical hormone that supports appetite regulation, metabolic health, and fat processing. This enhanced result further reinforces the effectiveness of the MindBody GLP-1 System in promoting sustainable, natural wellness through Activation. Key findings from LifeVantage’s U.S. clinical studies on the MindBody GLP-1 System include: Over 200% average increase in GLP-1 over 12 weeks; Average weight loss of 11 pounds within 12 weeks, with some participants losing up to 25 pounds; Up to 9% decrease in total body fat percentage; Up to 24% decrease in visceral fat; Up to 9% decrease in subcutaneous fat; Up to 6% increase in skeletal muscle; 100% of weight lost was from fat, not muscle.